First Reported Case of Pure Red Cell Aplasia Related to Sotorasib

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• KRAS G12C mutations are common drivers in advanced lung adenocarcinoma.
• Immune checkpoint inhibitors (ICIs) are standard first-line treatments.
• Sotorasib is an approved targeted therapy for KRAS G12C-mutated lung cancer.

Purpose of the Study:

• To report a rare adverse event associated with sotorasib treatment.
• To investigate the cause of new-onset anemia in a patient receiving sotorasib.
• To identify the specific drug responsible for the observed hematological toxicity.

Main Methods:

• Clinical case report of a 64-year-old male patient with advanced lung adenocarcinoma.
• Monitoring of laboratory parameters including hemoglobin, erythropoietin, and reticulocyte levels.
• Bone marrow aspiration for cytological and morphological evaluation.
• Causality assessment of drug-induced adverse events.

Main Results:

• The patient developed severe anemia with elevated erythropoietin and decreased reticulocytes.
• Bone marrow examination confirmed pure red cell aplasia.
• Discontinuation of sotorasib led to rapid improvement in hemoglobin levels, identifying it as the causative agent.

Conclusions:

• Sotorasib can induce pure red cell aplasia, a rare but serious hematological toxicity.
• Clinicians should monitor for anemia in patients treated with sotorasib, especially those with prior ICI exposure.
• Early recognition and drug withdrawal are crucial for managing sotorasib-induced anemia.